UNSPSC 51111660: Triciribine

This classification denotes a purine antagonist and inosine monophosphate dehydrogenase inhibitor and amidophosphoribosyltransferase inhibitor with the molecular formula C13H16N6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2421HMY9N6, chemically known as 1,4,5,6,8-pentaazaacennaphthylen-3-amine, 1,5-dihydro-5-methyl-1-beta-d-ribofuranosyl- (9ci) but generally known as triciribine, which bears US NIH Compound Identifier 65399.

UNSPSC 51111660 Triciribine is a Commodity code covering a single pharmaceutical active ingredient used in oncology research and clinical applications. State and local governments procure triciribine primarily through health departments, hospital systems, and research institutions that support cancer treatment programs, clinical trials, and laboratory research. The drug functions as a nucleoside analog with applications in leukemia and lymphoma treatment protocols, and procurement typically involves bulk pharmaceutical purchasing through established supplier networks or specialized oncology drug distributors.

The source provides no recent state and local contract opportunities tagged to this code. Without posted solicitations, the geographic scope of current procurement activity and representative recent issuing bodies cannot be determined from available data.